vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and National Bank Holdings Corp (NBHC). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $126.8M, roughly 1.5× National Bank Holdings Corp). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 14.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Old National Bank is an American regional bank with nearly 200 retail branches operated by Old National Bancorp and based in Chicago and Evansville, Indiana. With assets at $48.5 billion and 250 banking centers, Old National Bancorp is the largest financial services bank holding company headquartered in Indiana and one of the top 30 banking companies in the U.S. Old National Bank has locations in Illinois, Indiana, Iowa, Kentucky, Michigan, Minnesota, Tennessee, and Wisconsin.
AXSM vs NBHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $126.8M |
| Net Profit | — | $20.8M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 16.4% |
| Revenue YoY | 57.4% | — |
| Net Profit YoY | — | -14.2% |
| EPS (diluted) | — | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $126.8M | ||
| Q4 25 | $196.0M | $100.6M | ||
| Q3 25 | $171.0M | $108.9M | ||
| Q2 25 | $150.0M | $104.5M | ||
| Q1 25 | $121.5M | $102.1M | ||
| Q4 24 | $118.8M | $101.3M | ||
| Q3 24 | $104.8M | $106.0M | ||
| Q2 24 | $87.2M | $97.6M |
| Q1 26 | — | $20.8M | ||
| Q4 25 | $-28.6M | $16.0M | ||
| Q3 25 | $-47.2M | $35.3M | ||
| Q2 25 | $-48.0M | $34.0M | ||
| Q1 25 | $-59.4M | $24.2M | ||
| Q4 24 | $-74.9M | $28.2M | ||
| Q3 24 | $-64.6M | $33.1M | ||
| Q2 24 | $-79.3M | $26.1M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 19.0% | ||
| Q3 25 | -27.0% | 39.6% | ||
| Q2 25 | -24.5% | 39.8% | ||
| Q1 25 | -46.9% | 29.2% | ||
| Q4 24 | -61.1% | 34.3% | ||
| Q3 24 | -59.8% | 37.6% | ||
| Q2 24 | -89.5% | 32.5% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | -14.6% | 15.9% | ||
| Q3 25 | -27.6% | 32.4% | ||
| Q2 25 | -32.0% | 32.6% | ||
| Q1 25 | -48.9% | 23.7% | ||
| Q4 24 | -63.1% | 27.8% | ||
| Q3 24 | -61.7% | 31.2% | ||
| Q2 24 | -91.0% | 26.8% |
| Q1 26 | — | $0.46 | ||
| Q4 25 | $-0.55 | $0.42 | ||
| Q3 25 | $-0.94 | $0.92 | ||
| Q2 25 | $-0.97 | $0.88 | ||
| Q1 25 | $-1.22 | $0.63 | ||
| Q4 24 | $-1.54 | $0.72 | ||
| Q3 24 | $-1.34 | $0.86 | ||
| Q2 24 | $-1.67 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $472.8M |
| Total DebtLower is stronger | $70.0M | $202.1M |
| Stockholders' EquityBook value | — | $1.7B |
| Total Assets | $713.6M | $12.6B |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $472.8M | ||
| Q4 25 | $322.9M | $417.1M | ||
| Q3 25 | $325.3M | $555.6M | ||
| Q2 25 | $303.0M | $296.5M | ||
| Q1 25 | $300.9M | $246.3M | ||
| Q4 24 | $315.4M | $127.8M | ||
| Q3 24 | $327.3M | $180.8M | ||
| Q2 24 | $315.7M | $145.0M |
| Q1 26 | $70.0M | $202.1M | ||
| Q4 25 | — | $54.5M | ||
| Q3 25 | — | $54.7M | ||
| Q2 25 | — | $54.4M | ||
| Q1 25 | — | $54.6M | ||
| Q4 24 | — | $54.5M | ||
| Q3 24 | — | $54.4M | ||
| Q2 24 | — | $54.4M |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $88.3M | $1.4B | ||
| Q3 25 | $73.7M | $1.4B | ||
| Q2 25 | $73.1M | $1.4B | ||
| Q1 25 | $53.2M | $1.3B | ||
| Q4 24 | $57.0M | $1.3B | ||
| Q3 24 | $92.9M | $1.3B | ||
| Q2 24 | $102.9M | $1.2B |
| Q1 26 | $713.6M | $12.6B | ||
| Q4 25 | $689.8M | $9.9B | ||
| Q3 25 | $669.3M | $10.2B | ||
| Q2 25 | $639.8M | $10.0B | ||
| Q1 25 | $596.7M | $10.1B | ||
| Q4 24 | $568.5M | $9.8B | ||
| Q3 24 | $561.5M | $10.0B | ||
| Q2 24 | $548.2M | $10.0B |
| Q1 26 | — | 0.12× | ||
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
NBHC
| Net Interest Income | $108.8M | 86% |
| Noninterest Income | $18.0M | 14% |
